VNDA
vs
S&P 500
VNDA
S&P 500
Over the past 12 months, VNDA has significantly outperformed S&P 500, delivering a return of +44% compared to the S&P 500's +15% growth.
Stocks Performance
VNDA vs S&P 500
Performance Gap
VNDA vs S&P 500
Performance By Year
VNDA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vanda Pharmaceuticals Inc
Glance View
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The company is headquartered in Washington, Washington Dc and currently employs 278 full-time employees. The company went IPO on 2006-04-12. The company is focused on the development and commercialization of therapies to address unmet medical needs. Its commercial portfolio consists of two products, such as HETLIOZ (tasimelteon) and Fanapt (iloperidone). Tasimelteon is used for the treatment of jet lag disorder, delayed sleep phase disorder (DSPD), symptoms of autism spectrum disorder (ASD) and pediatric Non-24-Hour Sleep-Wake Disorder (Non-24). Iloperidone is used for the treatment of bipolar disorder and Parkinson's disease psychosis and is a long acting injectable (LAI) formulation for the treatment of schizophrenia. Its other product pipeline includes Tradipitant (VLY-686), VTR-297, VSJ-110 and BPO-27. VLY-686, is for the treatment of gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. VTR-297, is for the treatment of hematologic malignancies and use as a treatment for oncology indications. Its other products include VQW-765 and VHX-896.
